前列腺癌临床试验设计与目标:PCWG4推荐
PCWG4国际专家委员会于2016至2025年制定更新推荐,重新定义晚期前列腺癌疾病状态术语、 Eligibility标准、疗效终点及影像评估,强调PET成像与生物标志物指导的试验设计,并将指导扩展至未接受雄激素通路调节剂的早期疾病状态。
要点
- PCWG4更新晚期前列腺癌试验术语与终点,强调PET成像和生物标志物。
- 推荐涵盖疾病状态定义、入组标准、缓解与延迟/预防终点及评估间隔。
- 指导扩展至雄激素通路调节剂初治/敏感疾病状态。
核心结论
- PCWG4更新了患者与肿瘤特征、治疗开发及影像标准推荐,并扩展至更早疾病状态。
研究设计与样本
- 国际专家委员会PCWG4于2016至2025年制定,基于新兴证据与临床试验数据形成推荐。
主要发现
- PCWG4重新定义疾病状态和既往治疗术语,并聚焦PET定义的疾病。
- 提供疾病状态术语、入组标准、缓解与延迟/预防终点、再评估间隔及患者报告结局的新推荐。
关键数值与推荐
- 推荐在生物标志物背景下针对预期适应症反映患者获益。
- 强调开发验证性PET成像及分子和表型标准,以及风险分层和疗效评估的试验设计。
临床怎么用
- 用于指导晚期前列腺癌临床试验设计、入组和终点评估。
- 临床实践中可参考PCWG4术语和影像标准进行试验规划。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The continuous development of new imaging approaches, molecular phenotyping, genetic subtypes, prognosis assessments, and effective therapies across a range of disease states has created a need to redefine terminology and best practices for clinical trial conduct in patients with advanced prostate cancer. METHODS: We convened an international expert committee of diverse working groups, the Prostate Cancer Working Group 4 (PCWG4), between 2016 and 2025. Our objective was to formulate updated criteria based on emerging evidence and clinical trial data in a biomarker context to provide guidance for clinical trial design, eligibility, and end point assessments for patients with advanced prostate cancer. RESULTS: PCWG4 redefines terminology around the disease state and previous therapies in a patient-centric context and terminology focused on androgen pathway modulation. We consider imaging, with a particular focus on positron emission tomography (PET)-defined disease. New recommendations are provided for disease state terminology, defining eligibility criteria, response and delay/prevent end points, intervals for reassessments including imaging, and patient-reported outcome determination. We provide recommendations in a biomarker-based context of use for the intended indication, reflective of patient benefit for specific interventions. We emphasize the need for development of validated PET imaging and molecular and phenotypic criteria as well as trial designs to appropriately risk stratify patients, predict and assess benefit, and measure post-treatment outcomes reliably in a trial framework. CONCLUSION: PCWG4 updates recommendations on patient and tumor characterization, therapy development, and imaging criteria and extends guidance into earlier androgen pathway modulator-naïve/sensitive disease states to reflect an evolving, heterogeneous, and diverse patient population to optimize treatment benefits for all patients.
引用
- Armstrong AJ, Morris MJ, Abida W, et al. Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4. J Clin Oncol. 2026. PMID: 41744290. doi:10.1200/JCO-25-02834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。